Advertisement

aspirin Tablets (Buffered)

[04 August 2014]

Products Affected - Description

Products Affected - Description
Ascriptin Tablets, Novartis Consumer Health
325 mg tablets, 100 count (NDC 00067-0149-10)

Reason for the Shortage

  • Novartis has temporarily suspended manufacture of multiple drug products that were manufactured at the Lincoln facility including Bufferin and Ascriptin Tablets.
  • Novartis voluntarily recalled all lots of Bufferin Tablets with expiration dates of December 20, 2013 or earlier.
  • Novartis divested the rights for all Bufferin products to Ducere Pharma in early-2013.
  • Ducere Pharma re-introduced Bufferin tablets in late 2013.
  • Medique Products discontinued their buffered aspirin presentations in May, 2012.
  • Major states the shortage was due to increased demand for the product.
  • Teva discontinued their buffered aspirin products late 2009 and early 2010.

Available Products

Aspirin Tri-Buffered Tablets, Major
325 mg tablets, 100 count (NDC 00904-2015-59)
 
Bufferin Tablets, Ducere Pharma
325 mg tablets, 130 count (NDC 55741-0013-13)

Estimated Resupply Dates

Novartis has Ascriptin Tablets on back order and cannot estimate a release date. 

Related Shortages

Updated

August 4, 2014; May 29, 2014; March 27, 2014; January 29, 2014; November 21, 2013; September 19, 2013; July 12, 2013; May 6, 2013; March 8, 2013; January 4, 2013; December 19, 2012; October 31, 2012; September 5, 2012; July 31, 2012, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement